Disease · MONDO_0006733

dry eye syndrome

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dry eye syndrome. Diseases, record MONDO_0006733. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006733

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dry eye syndrome; Open Targets
Open Targets ID: MONDO_0006733; Open Targets
Other names: Dry Eye Syndromes, Dry eyes, Keraconjunctivitis sicca, Keratitis sicca, Keratoconjunctivitis sicca (disorder), Tear film insufficiency, Xerophthalmia, dry eye, dry eye(s), eye(s), dry, keratoconjunctivitis sicca, sicca, keratoconjunctivitis; Open Targets
Disease Ontology: DOID:10140; Disease Ontology
Disease Ontology: DOID:12895; Disease Ontology
MeSH: D007638; MeSH
MeSH: D015352; MeSH
NCI Thesaurus: C34553; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 91 drugs, from DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs91

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOSPORINE	CHEMBL160	Protein	Approval	EMA Human Drugs	41	38	38	Drugs and targets
LIFITEGRAST	CHEMBL2048028	Small molecule	Approval	FDA	11	10	10	Drugs and targets
REBAMIPIDE	CHEMBL1697771	Small molecule	Approval	PMDA	10	9	9	Drugs and targets
LOTEPREDNOL ETABONATE	CHEMBL1200865	Small molecule	Approval	DailyMed	7	6	6	Drugs and targets
PERFLUOROHEXYLOCTANE	CHEMBL5314588	Small molecule	Approval	FDA	3	1	1	Drugs and targets
DIQUAFOSOL TETRASODIUM	CHEMBL1767408	Small molecule	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
HYALURONATE SODIUM	CHEMBL4594244		Phase 3	ClinicalTrials.gov	11	11	11	Drugs and targets
CARBOXYMETHYLCELLULOSE SODIUM	CHEMBL2109001		Phase 3	ClinicalTrials.gov	9	9	5	Drugs and targets
HYALURONIC ACID	CHEMBL5314376		Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
OZAGREL	CHEMBL11662	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets

1 to 10 of 91

See all 91 drugs

Targets52

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	11	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	3	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 3	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	2	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 3	https://conductscience.org/library/genes/1141	Drugs and targets
P2RY1	P2Y purinoceptor 1	2	Purinergic receptor P2Y1 agonist	Phase 3	https://conductscience.org/library/genes/5028	Drugs and targets
P2RY2	P2Y purinoceptor 2	2	Purinergic receptor P2Y2 agonist	Phase 3	https://conductscience.org/library/genes/5029	Drugs and targets
P2RY4	P2Y purinoceptor 4	2	Pyrimidinergic receptor P2Y4 agonist	Phase 3	https://conductscience.org/library/genes/5030	Drugs and targets
P2RY6	P2Y purinoceptor 6	2	Pyrimidinergic receptor P2Y6 agonist	Phase 3	https://conductscience.org/library/genes/5031	Drugs and targets
PTGS1	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5742	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor	Phase 2	https://conductscience.org/library/genes/5743	Drugs and targets

1 to 10 of 52

See all 52 targets

Trials187

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04735393	A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease	Phase 3	757	2025-11-26	Dry Eye Disease	REPROXALAP	Open Targets' reading of its record	ClinicalTrials.gov
NCT02688556	Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca	Phase 3	745	2019-04-08	Keratoconjunctivitis Sicca	CYCLOSPORINE	Its record names the disease	ClinicalTrials.gov
NCT01276223	Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients	Phase 2	722	2013-03-11	Dry Eye Disease	DIFLUPREDNATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01743729	A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye	Phase 3	720	2017-02-24	Dry Eye Disease	LIFITEGRAST	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02284516	A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)	Phase 3	711	2017-03-15	Dry Eye Disease	LIFITEGRAST	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03925727	Tavilermide Ophthalmic Solution for the Treatment of Dry Eye	Phase 3	623	2023-03-09	Keratoconjunctivitis Sicca, Dry Eye	TAVILERMIDE	Its record names the disease	ClinicalTrials.gov
NCT04567329	Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)	Phase 3	620	2024-08-19	Dry Eye Disease	PERFLUOROHEXYLOCTANE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02974907	Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2	Phase 3	601	2022-01-05	Dry Eye Syndrome	TIMBETASIN ACETATE	Its record names the disease	ClinicalTrials.gov
NCT01421498	Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)	Phase 3	588	2017-02-24	Keratoconjunctivitis Sicca, Dry Eye Disease	LIFITEGRAST	Its record names the disease	ClinicalTrials.gov
NCT04147650	Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome	Phase 2/3	508	2021-12-10	Dry Eye Syndrome, Keratoconjunctivitis Sicca	VOCLOSPORIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 187

See all 187 trials

Comparisons in its trials67

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Reproxalap vs Vehicle: TE-SAEs of the Retina	0 of 503	0 of 251	754	NCT04735393	Trial comparisons
Reproxalap vs Vehicle: TE-SAEs of Increase in Intraocular Pressure	0 of 503	0 of 251	754	NCT04735393	Trial comparisons
Reproxalap vs Vehicle: Treatment-Emergent Serious Adverse Events (TE-SAEs) of Visual Acuity Decrease	0 of 503	0 of 251	754	NCT04735393	Trial comparisons
Reproxalap vs Vehicle: TE-SAEs of the Cornea	0 of 503	0 of 251	754	NCT04735393	Trial comparisons
OTX-101 0.09% vs Vehicle: deaths from any cause	1 of 372	0 of 372	744	NCT02688556	Trial comparisons
OTX-101 0.09% vs Vehicle: serious adverse events	6 of 372	2 of 372	744	NCT02688556	Trial comparisons
Lifitegrast vs Placebo: serious adverse events	3 of 359	4 of 359	718	NCT01743729	Trial comparisons
Lifitegrast vs Placebo: serious adverse events	4 of 357	4 of 354	711	NCT02284516	Trial comparisons
NOV03 vs Saline Solution: deaths from any cause	0 of 311	0 of 309	620	NCT04567329	Trial comparisons
NOV03 vs Saline Solution: serious adverse events	0 of 311	0 of 309	620	NCT04567329	Trial comparisons

1 to 10 of 67

See all 67 comparisons in its trials

Papers from its trials77

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37209594	RESULT	1	PubMed
34481407	RESULT	1	PubMed
33561944	RESULT	1	PubMed
33342317	RESULT	1	PubMed
33296261	RESULT	1	PubMed
32836200	RESULT	1	PubMed
32280196	RESULT	1	PubMed
31763712	RESULT	1	PubMed
31373862	RESULT	1	PubMed
31083981	RESULT	1	PubMed

1 to 10 of 77

See all 77 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006733

GET https://conductscience.org/api/diseases/v1/MONDO_0006733/drugs?page=2

API reference For AI assistants